Neurolief Overview

  • Founded
  • 2013
  • Status
  • Private
  • Employees
  • 19
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $4.9M
Latest Deal Amount
  • Investors
  • 3

Neurolief General Information


Developer of a brain neuromodulation device designed to bring relief to patients suffering from chronic neurological and neuropsychiatric disorders. The company's device offers adaptive, self-learning treatment using a digital therapeutics platform and can be used to treat depression, migraine and insomnia, enabling patients to have an effective treatment without the risks and costs associated with invasive procedures and without the side effects associated with medications.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Application Software
Other Healthcare Technology Systems
Primary Office
  • 12 Giborei Israel
  • Netanya 4250412
  • Israel
+972 00-000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Neurolief Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 09-May-2018 $4.9M 00.00 000.00 Completed Generating Revenue
1. Seed Round 01-Jan-2015 00.00 00.00 Completed Generating Revenue
To view Neurolief’s complete valuation and funding history, request access »

Neurolief Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preferred A1 000,000 00.000000 00.00 00.00 00 00.00 0.000
Preferred A 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
To view Neurolief’s complete cap table history, request access »

Neurolief Executive Team (3)

Name Title Board Seat Contact Info
Shmuel Shany Co-Founder, Chief Executive Officer & President
Brent Metzler Chief Financial Officer
Amit Dar Ph.D Co-Founder & Chief Technology Officer
To view Neurolief’s complete executive team members history, request access »

Neurolief Board Members (1)

Name Representing Role Since
Chris Richardson Self Chairman 000 0000
To view Neurolief’s complete board members history, request access »

Neurolief Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neurolief Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Champel Capital Venture Capital Minority 000 0000 000000 0
KT Squared Venture Capital Minority 000 0000 000000 0
Terra Venture Partners Venture Capital Minority 000 0000 000000 0
To view Neurolief’s complete investors history, request access »